1+ day, 15+ min ago   (323+ words) Last week’s regulatory news saw the US Food and Drug Administration (FDA) grant accelerated approval for AstraZeneca’s Etcamah combination for the treatment of breast cancer. On the research front, Novartis suffered another setback, this time with its Phase III trial…...

4+ day, 1+ hour ago   (209+ words) The Pharma Letter - Solstice Oncology launches with $225 million to advance neoadjuvant CTLA-4 antibody USA-based Solstice Oncology has launched with a $225 million Series A financing to advance porustobart, a second-generation, Fc-enhanced CTLA-4 antibody, into neoadjuvant treatment of colon cancer. The round…...

4+ day, 22+ hour ago   (230+ words) The Pharma Letter - Kura launches new company, diabetes focused Caspian Therapeutics US biotech Kura Oncology (Nasdaq: KURA) today announced the launch of Caspian Therapeutics, a separately financed company established to advance small-molecule menin inhibitors for diabetes and cardiometabolic diseases. Caspian…...

2+ week, 6+ day ago   (227+ words) The Pharma Letter - Revier launches with six million euros seed round to develop class IIa HDAC inhibitors for cardiometabolic disease German biotech Revier Therapeutics has launched operations following the close of a six million euros ($6.45 million) seed financing round, the…...

3+ week, 2+ day ago   (588+ words) The Pharma Letter A clinical-stage biopharmaceutical company focused on WEE1 inhibition in biomarker-selected ovarian cancer, with its lead asset azenosertib approaching a pivotal registration-enabling data readout in 2026. Zentalis Pharmaceuticals discovers and develops small molecule therapeutics targeting fundamental biological pathways in cancer....

3+ week, 3+ day ago   (258+ words) The Pharma Letter Edesa Biotech prices $25 million public offering Canada-based Edesa Biotech (Nasdaq: EDSA) has priced an underwritten public offering expected to generate approximately $25 million in gross proceeds. The company’s shares slumped 17.2% to $4.76 following the announcement. The offering includes 3,870,500 common…...

3+ week, 4+ day ago   (243+ words) The Pharma Letter - Kynexis raises 97 million euros to advance med for cognitive disorders Dutch clinical-stage biotech Kynexis today announced the closing of a 40 million euros ($46.3 million) Series A extension bringing total Series A financing to 97 million euros ($110 million). The financing…...

4+ week, 1+ day ago   (314+ words) Deal-making news last week including Spanish dermatology specialist Almirall entering into a research collaboration with China’s CrystalO Biopharma. Sentynl entered a deal to license lung disease candidate alvelestat from Mereo BioPharma, which could earn the latter nearly half a billion…...